Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Synthetic Biologics stock | $0.39

Own Synthetic Biologics stock in just a few minutes.

Fact checked

Synthetic Biologics, Inc is a biotechnology business based in the US. Synthetic Biologics shares (SYN) are listed on the NYSE MKT and all prices are listed in US Dollars. Synthetic Biologics employs 11 staff and has a market cap (total outstanding shares value) of USD$7.4 million.

How to buy shares in Synthetic Biologics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Synthetic Biologics. Find the stock by name or ticker symbol: SYN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Synthetic Biologics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.39, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Synthetic Biologics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Synthetic Biologics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Synthetic Biologics share price

Use our graph to track the performance of SYN stocks over time.

Synthetic Biologics shares at a glance

Information last updated 2020-12-04.
Latest market closeUSD$0.39
52-week rangeUSD$0.25 - USD$0.688
50-day moving average USD$0.3414
200-day moving average USD$0.4504
Wall St. target priceUSD$1.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.123

Buy Synthetic Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Synthetic Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synthetic Biologics price performance over time

Historical closes compared with the close of $0.39 from 2020-12-09

1 week (2021-01-12) N/A
1 month (2020-12-23) 8.33%
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Synthetic Biologics financials

Gross profit TTM USD$0
Return on assets TTM -50.27%
Return on equity TTM -120.29%
Profit margin 0%
Book value $0.006
Market capitalisation USD$7.4 million

TTM: trailing 12 months

Shorting Synthetic Biologics shares

There are currently 317,008 Synthetic Biologics shares held short by investors – that's known as Synthetic Biologics's "short interest". This figure is 799.7% up from 35,234 last month.

There are a few different ways that this level of interest in shorting Synthetic Biologics shares can be evaluated.

Synthetic Biologics's "short interest ratio" (SIR)

Synthetic Biologics's "short interest ratio" (SIR) is the quantity of Synthetic Biologics shares currently shorted divided by the average quantity of Synthetic Biologics shares traded daily (recently around 566085.71428571). Synthetic Biologics's SIR currently stands at 0.56. In other words for every 100,000 Synthetic Biologics shares traded daily on the market, roughly 560 shares are currently held short.

However Synthetic Biologics's short interest can also be evaluated against the total number of Synthetic Biologics shares, or, against the total number of tradable Synthetic Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synthetic Biologics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Synthetic Biologics shares in existence, roughly 20 shares are currently held short) or 0.0159% of the tradable shares (for every 100,000 tradable Synthetic Biologics shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synthetic Biologics.

Find out more about how you can short Synthetic Biologics stock.

Synthetic Biologics share dividends

We're not expecting Synthetic Biologics to pay a dividend over the next 12 months.

Have Synthetic Biologics's shares ever split?

Synthetic Biologics's shares were split on a 1:35 basis on 13 August 2018. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synthetic Biologics shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Synthetic Biologics shares which in turn could have impacted Synthetic Biologics's share price.

Synthetic Biologics share price volatility

Over the last 12 months, Synthetic Biologics's shares have ranged in value from as little as $0.25 up to $0.688. A popular way to gauge a stock's volatility is its "beta".

SYN.US volatility(beta: 2.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Synthetic Biologics's is 2.2934. This would suggest that Synthetic Biologics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Synthetic Biologics overview

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site